Lineage Cell Therapeutics, Stock Net Asset
| LCTX Stock | ILA 211.20 209.09 9,909% |
Lineage Cell Therapeutics, fundamentals help investors to digest information that contributes to Lineage Cell's financial success or failures. It also enables traders to predict the movement of Lineage Stock. The fundamental analysis module provides a way to measure Lineage Cell's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lineage Cell stock.
Lineage |
Lineage Cell Therapeutics, Company Net Asset Analysis
Lineage Cell's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Based on the recorded statements, Lineage Cell Therapeutics, has a Net Asset of 0.0. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Net Asset (which currently averages 0.0) industry. This indicator is about the same for all Israel stocks average (which is currently at 0.0).
Lineage Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lineage Cell's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lineage Cell could also be used in its relative valuation, which is a method of valuing Lineage Cell by comparing valuation metrics of similar companies.Lineage Cell is currently under evaluation in net asset category among its peers.
Lineage Fundamentals
| Return On Equity | -10.82 | |||
| Return On Asset | -13.19 | |||
| Current Valuation | 1.3 B | |||
| Shares Owned By Insiders | 4.50 % | |||
| Shares Owned By Institutions | 43.81 % | |||
| Revenue | 1.83 M | |||
| Gross Profit | 1.44 M | |||
| EBITDA | (24.77 M) | |||
| Net Income | (11.93 M) | |||
| Cash And Equivalents | 68.75 M | |||
| Cash Per Share | 0.41 X | |||
| Total Debt | 2.9 M | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 10.58 X | |||
| Book Value Per Share | 0.63 X | |||
| Cash Flow From Operations | (23.33 M) | |||
| Earnings Per Share | (0.14) X | |||
| Number Of Employees | 49 | |||
| Beta | 1.84 |
About Lineage Cell Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lineage Cell Therapeutics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lineage Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lineage Cell Therapeutics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Lineage Stock
Lineage Cell financial ratios help investors to determine whether Lineage Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Lineage with respect to the benefits of owning Lineage Cell security.